Current Headlines

1. iBio Technology Produces Vaccine Candidate For Recently Emerged H7N9 Influenza
   5/22/2013

   iBio, Inc. (NYSE MKT: IBIO) today announced the production of a vaccine candidate for the newly emerged H7N9 influenza virus by an independent third party laboratory using the iBioLaunch™ platform.

2. NIH Funds Studies To Improve Type 2 And Prediabetes Treatment
   5/22/2013

   The National Institutes of Health is looking for volunteers to take part in one of three clinical trials to improve and preserve the production of insulin in people with prediabetes or recently diagnosed type 2 diabetes.

3. Mayo Clinic Forms Joint Venture With Cancer Genetics
   5/22/2013

   Mayo Clinic ("Mayo") and Cancer Genetics Inc. recently launched OncoSpire Genomics ("OncoSpire"), a joint venture with the singular goal of improving cancer care by discovering and commercializing diagnostic tests that leverage next-generation sequencing.

4. Global Vision's Text Comparison Software Docu-Proof Recognized By The EMA For Regulatory Submissions
   5/21/2013

   Global Vision, the industry leader in the development of automated proofreading solutions, recently announced that Docu-Proof has met compliance requirements as a text comparison software solution by the European Medicines Agency (EMA) for pharmaceutical companies using parallel distribution methods of medicinal products.

5. Drawing Closer To Alzheimer’s Magic Bullet?
   5/21/2013

   Imagine a pharmaceutical prevention, treatment or even cure for Alzheimer’s disease. By Jonathan Riggs

6. Study Shows Whole-Cell Vaccine Was More Effective Than Acellular Vaccine During California Pertussis Outbreak
   5/20/2013

   Whole-cell pertussis vaccines were more effective at protecting against pertussis than acellular pertussis vaccines during a large recent outbreak, according to a new Kaiser Permanente study published in Pediatrics.

7. Novozymes Biopharma’s Recombinant Human Albumin Helps Innovative Dry Eye Therapy Move Into Clinical Trials
   5/20/2013

   Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, recently announced that an ophthalmic solution made using its recombinant human albumin, has been approved for Phase I/II development by the FDA.

8. The Start-Up Elsalys Biotech, A New Player In The Therapeutic Monoclonal Antibody Arena, Announces The First Round Of Financing With Transgene And Sofimac Partners
   5/17/2013

   ElsaLys Biotech, which specializes in the development of therapeutic monoclonal antibodies, announces a first round of financing of 2.1M€ from the biopharmaceutical company Transgene and the investment fund Sofimac Partners.

9. Seminars, Technology Highlight CYTO 2013 Offerings From Beckman Coulter Life Sciences
   5/16/2013

   Presenting two seminars and seven poster sessions, Beckman Coulter Life Sciences will have a prominent role when CYTO 2013 convenes at the San Diego Convention Center May 18-22, 2013.

10. MultiCell Technologies Files U.S. Patent Application For Targeted Delivery Of Noncoding Micro RNAs For The Treatment Of Liver Cancer
    5/16/2013

    MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) is pleased to announce the filing of a U.S. patent application concerning methods and formulations to achieve targeted tumor cell death.  MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro models of hepatocellular carcinoma.